---
title: "ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors"
description: "SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that add"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262917718.md"
published_at: "2025-10-27T13:37:43.000Z"
---

# ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

> SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( Nasdaq: ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR ...

### Related Stocks

- [ORIC.US - ORIC Pharmaceuticals](https://longbridge.com/en/quote/ORIC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25 | Oric Pharmaceuticals (NASDAQ:ORIC) outlined its 2025 milestones at the Guggenheim Biotech Conference, including plans to | [Link](https://longbridge.com/en/news/275985972.md) |
| Oric Pharmaceuticals Reports Promising Phase 1b Results for ORIC-944 in Prostate Cancer Trial | Oric Pharmaceuticals Inc. announced promising results from its Phase 1b trial of ORIC-944 for metastatic castration-resi | [Link](https://longbridge.com/en/news/265787491.md) |
| 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across  | [Link](https://longbridge.com/en/news/276139832.md) |
| 11:03 ETNew Guidelines from NCCN Detail Fundamental Differences in Cancer in Children Compared to Adults | The National Comprehensive Cancer Network (NCCN) has released new Clinical Practice Guidelines for Pediatric Soft Tissue | [Link](https://longbridge.com/en/news/276145789.md) |
| ZAWYA-PRESSR: Burjeel Medical City launches Sarcoma & Bone Center to strengthen care for rare and complex cancers | Burjeel Cancer Institute has launched a specialized Sarcoma & Bone Center at Burjeel Medical City in Abu Dhabi, enhancin | [Link](https://longbridge.com/en/news/275995782.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.